As previous studies from our laboratory showed AB680 reduces the growth of KPC tumors (20) when tumors were treated starting early in tumor development, in this work we evaluated in our preclinical syngeneic PDA model an in vivo CD73 inhibition with AB680 in combination with RFA and observed a more significant decrease in tumor growth when AB680 is used in combination with RFA. This evidence concerns the gene NT5E and Patent ductus arteriosus.